secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001493152-24-030771
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte reports Q2 revenue $104K, loss $0.36/sh; launches GraftAssure at two centers
--------------------------------------------------------------------------------

- Revenue of $104K from pharma services; operating expenses $4.7M; loss from ops $4.5M ($0.36/sh).
- GraftAssure RUO assay used at two transplant centers in U.S. and Southeast Asia in July 2024.
- Sales funnel represents centers covering ~25% of annual U.S. transplant volumes (11,000+ transplants).
- Appointed Andrea James as CFO; she previously led IR at Axon and helped raise >$550M in equity.
- Cash & equivalents $11.0M at June 30, up $3.7M sequentially; includes $1.7M restricted cash.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315224030771/0001493152-24-030771-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315224030771/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-030771

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer